Drug intelligence / Profile preview

curcuphenol

Development stage: Preclinical
Lead developer: Cava Healthcare
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Curcuphenol is a natural product small molecule under development by Cava Healthcare for the treatment of metastatic cancer. It exhibits a novel mechanism of action by enhancing histone deacetylase (HDAC) activity, which helps counter immune escape pathways in metastatic tumors. This immune-driven attenuation of tumor growth distinguishes it from traditional HDAC inhibitors. The compound is derived from natural sources and is being explored for its ability to modulate the tumor microenvironment and prevent the progression of advanced cancers.

Other names: curcuphenolscurcuphenol analogs

Targets

HDAC8 (Histone Deacetylase 8)HDAC5 (Histone deacetylase 5)HDAC10 (Histone Deacetylase 10)

Beyond the preview

Go deeper on curcuphenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on curcuphenol.

Explore the full profile